Journal Menu
► ▼ Journal Menu-
- Current Oncology Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Early Career Editorial Board
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Volumes not published by MDPI
Need Help?
Announcements
30 August 2024
Meet Us at the 37th Annual Congress of the European Association of Nuclear Medicine, 19–23 October 2024, Hamburg, Germany
The 37th Annual Congress of the European Association of Nuclear Medicine, organized by the European Association of Nuclear Medicine, will be held from 19 to 23 October 2024, in Hamburg, Germany.
This conference will offer a platform to exchange and discuss the latest theranostic advances, alongside the most impactful clinical evidence, recently developed radiopharmaceuticals, and novel imaging and detection technologies. Several topics will be discussed during the “Technologists’ Track”, including, among many others, whole-body multimodality imaging principles, PET-CT in oncologic disease-staging applications, radio-guided surgery, brain PET studies, and recent advancements regarding artificial intelligence and radiomics, as well as one of the most relevant aspects of healthcare—patient advocacy.
The following MDPI journals will be represented at the conference:
- Diagnostics;
- Neurology International;
- Journal of Clinical Medicine;
- Medicina;
- Cancers;
- Children;
- Imaging;
- Tomography;
- Sci;
- Current Oncology.
If you are attending this conference, please feel free to start a conversation by contacting us online. Our delegates look forward to meeting you in person at our booth and answering any questions that you may have. For more information about the conference, please visit the following link: https://eanm24.eanm.org/.
19 August 2024
MDPI’s 2023 Young Investigator Awards—Winners Announced
MDPI’s Young Investigator Awards recognize promising early career scientists, acknowledge their contributions, and foster collaboration within the scientific community. We are proud to announce the recipients for 2023, who were carefully selected by the journals’ esteemed Award Evaluation Committee.
We extend our heartfelt congratulations to the 79 winners of MDPI’s 2023 Young Investigator Awards for their excellent contributions in their research field. We look forward to seeing these rising stars continue to contribute to the advancement of science.
MDPI will continue to support and recognize the academic community. To explore details about the awardees by field, please visit the individual pages listed below:
Congratulations to all the winners for their exceptional contributions and dedication to advancing scientific research.
About MDPI Awards:
To support the academic community, particularly young researchers, and to enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help to elevate the profiles of talented individuals who have made outstanding achievements and are making significant contributions to advancements in their respective fields.
To find out more about MDPI awards, please click here.
7 August 2024
MDPI Insights: The CEO's Letter #14 - New Headquarters, Marketing, Poland
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts

MDPI Moves to New Headquarters in Basel, Switzerland

I am excited to share that MDPI has moved to a new state-of-the-art office space in Basel, Switzerland. This move consolidates our operations by bringing together our two previously separated Basel offices into one central location.
We are always growing our talent pool and encourage you to view our Careers Page for the positions available in Basel and across our offices.
New Address: Grosspeteranlage 5, CH-4052 Basel, Switzerland
Effective Date: 1 July 2024
This new chapter in our company’s journey is designed to continue our mission of positioning MDPI as a leader in Open Access (OA) publishing, highlighting our commitment to making scholarly research accessible to everyone.

Boasting modern amenities, improved meeting and event spaces designed to support our growing needs, the new location provides a more collaborative and efficient working environment for our employees. The location offers convenient accessibility to public transportation and is situated near the Basel SBB railway station, with a variety of nearby services and amenities.
In fact, I can see the trains right outside of my window as I write these lines!
This move marks an exciting milestone in MDPI’s development, and I am confident that the new headquarters will serve as an inspiring and productive space for everyone. We also very much look forward to welcoming visitors here. You can read more about MDPI's history here.
“This new chapter continues our mission of positioning MDPI as a leader in OA publishing”
For Those New to MDPI
A pioneer in scholarly, Open Access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to Open Science by making a greater proportion of the research conducted worldwide free and accessible to everyone. To date, over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6,000 professional, well-trained staff members, and an in-house article submission platform designed to ensure efficient processes within its 440 fully Open Access titles. MDPI supports more than 800 academic institutions worldwide, helping them adhere to national mandates while facilitating authors’ publication in fully compliant (CC BY) Open Access journals.
Impactful Research

New and Emerging MDPI Journals Making an Immediate Impact
Unpacking some of the Impact Factor updates from the June CEO Letter, I wanted to dive a little deeper into the 137 MDPI journals which received Impact Factor for the first time.
Academic authors highly value efficient publishing processes, robust editorial support, and the opportunity to publish in high-impact journals. We are proud that our newly launched journals typically achieve coverage in the Emerging Sources Citation Index (ESCI) of the Web of Science within just a few years, with a median time of only three years from release to inclusion.
As part of our commitment to advancing academic research and providing high-quality OA publishing, we actively seek new research areas to expand our portfolio of journals. We have a proven track record of successfully establishing new journals.
Our dedicated teams excel in fostering dynamic editorial boards and working closely with Editors-in-Chief (EiC) to define the precise scope and focus of each new journal. Our expertise extends to collaborating with indexing services, ensuring that our journals comply with best practices and are indexed promptly in all relevant databases.
Emerging Titles Ranked for the First Time
Our commitment to excellence is reflected in the annual impact metrics released this past June. The latest edition of the Journal Citation Reports (JCR) showcases the integration of journals from the ESCI in the new unified category rankings, providing a simplified and more complete view of all journals within each subject category, including newly established titles.
Out of 137 new and developing MDPI journals ranked in the 2024 release, 79 are in the top half (Q1 or Q2) of their categories. Here is a breakdown of the number of MDPI’s ESCI-indexed journals by quartile in the JCR:
| Quartile | No. of journals |
| Q1 | 17 (12.4%) |
| Q2 | 62 (45.3%) |
| Q3 | 43 (31.4%) |
| Q4 | 15 (10.9%) |
| Not ranked (humanities-related journals) | 2 |
These rankings highlight our success in rapidly establishing high-impact new journals. Among those that made it directly into the top 25% of their category are the International Journal of Neonatal Screening, Journal of Xenobiotics, Polysaccharides, Smart Cities, and thirteen other journals.
You can browse MDPI journals by Indexing. Simply visit our Journals page and select from the list of Indexing bodies in the top left-hand corner.
Inside MDPI

MDPI Corporate Marketing Strategy and Team Meeting 2024
In July, I hosted the annual Corporate Marketing strategy and team-building activity with 15 of our team members.

The aim was to align the Corporate Marketing strategy with MDPI's goal of becoming the world's most trusted OA publisher. While we provide a high-level publishing experience for our authors, as seen from our surveys, we need to keep building on our transparent and open communication to foster trust within the scholarly community and continue enhancing our reputation.
The Corporate Marketing team plays an important role as the mouthpiece for all our major activities within MDPI, especially those that model what it means to be a trusted partner. The purpose of the strategy meeting was to develop a feeling of trust in one another and an understanding of how to inspire trust in the stakeholders with whom we interact.
“We need to keep building on our transparent and open communication to foster trust within the scholarly community”

We conducted a set of activities to facilitate that sense of mutual trust and trustworthiness. Examples of some activities we worked on during this strategy-building event include:
- Exploring what trust means
- ‘Letter to self’
- ‘The brand I most trust’
- Most Trusted Academic Publisher
- ‘The brand I would like MDPI to become’
- ‘The 2029 MDPI Annual Report’
- Voice of Customer and Share of Voice – survey/data update on MDPI Brand Experience and Brand Perception
- Integrate Trust-Based Objective into Marketing Plan
- ‘Becoming the MDPI experience’
- ‘Trusting the next steps’
While two days is not enough to finalize a marketing strategy, it is sufficient to get everyone who attended into the mindset of the direction in which we are working. From here, we will develop a program with next steps on main projects, update communications, and collaborate with team leads to incorporate this approach into our work going forward.
As a marketing team, we can communicate our messages, but trust has to be built at every touchpoint in the stakeholder journey. Just talking about it isn’t enough. We need to be about it. That’s a role each of us plays, from editorial to IT, from marketing to HR. We must build trust from the inside out. It starts with each manager and resonates out via every team member.
As a company, our goal is to give all stakeholders with whom we interact – whether internal or external – the experience of working with an organization it can trust.
Coming Together for Science

MDPI in Poland: Krakow Office
In July, I had the pleasure of visiting our Krakow office, following my recent trip to Warsaw to meet with the Polish Ministry of Science and Higher Education.

During these visits, I prioritized meeting with our Office Manager, Editorial Director, Group Leads, and members from various teams, including editorial, production, marketing, and journal relationship specialists, to understand their roles and current challenges. Instead of a formal presentation, I opted for an open discussion, sharing updates from headquarters to engage with colleagues in a more personal way.
Our Krakow office has many things to be proud of, including a large number of PhD colleagues (over a third of its staff holds a PhD degree). Krakow provides an opportunity for expanding beyond the 100 colleagues we currently have, by adding new hires in departments including editorial, production and marketing, among others.
About our Krakow office
- Opened in 2020
- 99 staff members as at 1 August 2024
- Main Departments include Editorial, Production, English Department, JRS, PR
Our Krakow office participates in international conferences, conducts author trainings and scholar visits, and engages in local market outreach. The office is also a member of the Polish Chamber of Commerce for High Technology (IZTECH) and is working on expanding its local engagement.
Krakow is the second-largest city in Poland, with a population of about 800,000. It also has a large student population of around 128,000, with seven universities. This means that roughly one in every eight residents is a student.
Poland and MDPI

Poland is a crucial market for MDPI. From 2020 to June 2024, Poland ranked 7th in submissions and 5th in publications for MDPI research articles. As at 31 July 2024, Poland ranks 7th in total MDPI publications, with approximately 70,000 research papers.
Between 2020 and June 2024, 61,500 authors from Poland published with MDPI. As at 30 June 2024, there are 1,205 active Editorial Board Members (EBMs) from Poland, with 661 EBMs (55% of the total) having an H-index over 25.
We also have four Editors-in-Chief (EiC) from Poland leading our journals: Coatings, Venereology, Advances in Respiratory Medicine, and Limnological Review, along with six Section EiC.
In 2023, we received approximately 21,000 submissions from Polish-affiliated authors, of which 12,032 were published.
“Poland is a crucial market for MDPI”
Meeting with Ministry of Education

On 22 July, we visited Warsaw to meet with the Polish Ministry of Science and Higher Education.
We were pleased to learn that they are strong supporters of the OA publishing model and value MDPI’s approach to the peer-review process, including our high ethical standards for quality control.
In 2023 Polish authors predominantly published their papers in OA, with MDPI holding the largest market share in OA publications within the country.
Our commitment to collaborating with Polish institutions is evident through our 33 Institutional Open Access Program (IOAP) agreements with prestigious institutions such as the University of Warsaw, the University of Wroclaw, the Jagiellonian University, and Gdańsk University of Technology. Through IOAP discounts, a healthy waiver rate, and our peer-review voucher system, we provide the Polish scholarly community with significant savings in OA publishing. The Minister greatly appreciated these efforts and our commitment to offsetting some of the APC costs.
We discussed industry concerns about the threat of papermills and presented the preventive measures MDPI has in place to mitigate this risk and uphold high ethical standards. We informed them of our commitment to combating papermills, including our involvement with United2Act and the STM Research Integrity Hub, as well as our efforts to expand our research integrity team and explore proactive measures.
Closing Thoughts

MDPI Thought Leadership Op-ed on Open Access is Now Live on Politico
I am pleased to share that our thought leadership Op-ed piece on Open Access (OA) is now live on Politico. This is a nice push for continued influence and support of OA among policymakers and industry leaders.
Why Politico?
Politico's reputation as a highly credible and influential news platform makes it an important venue to reach key opinion leaders (KOL) from academia, policymakers, and thought leaders from many industries. This visibility helps promote the OA philosophy.
Open Access: A Moral Imperative for Progress
In this piece, I discuss the necessity of making scientific research freely available to all. I argue that publicly funded research should be publicly accessible, highlighting how OA democratizes scientific knowledge, accelerates research availability, and fosters collaboration.
“Open Access is a fundamental right for all citizens”
Democratizing scientific communication
The impulse to democratize scientific communication is nothing new. OA may seem like a recent innovation, but its principles have historical roots traceable to Europe in the 15th century. Just as the printing revolution accelerated the dissemination of new ideas, OA publishing unlocks new scientific insights that would otherwise only be accessible to a few.
Benefits for scholars: amplifying impact through Open Access
Authors publishing in an OA journal can expect more citations of their work, increasing its potential impact. Research findings that are freely available are more likely to be cited than those hidden behind a paywall. Freedom of access greatly increases the potential audience for each paper, fostering a sense of community among researchers worldwide. Heightened visibility can attract prospective collaborators and employers for young scientists. At MDPI, we believe that all these factors can only accelerate the advance of science. Additionally, authors retain copyright in their work instead of signing it away, permitting broader dissemination under Creative Commons licenses and increasing its capacity for impact.
The moral imperative
OA is not just a matter of scientific policy; it is a fundamental right for all citizens and a prerequisite for a brighter, more informed future. Publicly funded research should be a top priority, and I am pleased to see policy moving in this direction. Our capacity to generate transformative scientific insights has to be democratized. The question today is no longer whether we can afford to embrace OA; rather, it is whether we can afford not to.
Chief Executive Officer
MDPI AG
2 August 2024
MDPI Romania Author Training Sessions in May
In May, MDPI Romania held three author training sessions – one endorsing an external event and two stand-alone sessions.
The National Session of Scientific Student Communications took place at Technical University Cluj on 17 and 18 May 2024. MDPI Romania sponsored this event and contributed an author training session on the production of research papers and case study analyses. JRS Norbert Kiss gave a presentation called The World of Open Access to explain different open access publishing models and the benefits of open access publishing. His presentation highlighted the impact of open access publishing on scientific progress and innovation.

On 29 May 2024, MDPI Romania hosted an author training session for Ph.D. students, early career researchers, and professors at the Carol Davila University of Medicine and Pharmacy. In collaboration with Prof. Andreea Arsene, JRS Ioana Paunescu prepared two presentations: The Steps of the Publishing Process and Elaboration of a Peer Review Report. In her first presentation, she delved into MDPI’s history and mission, MDPI’s editorial process, and MDPI journals of various scopes that are accepting submissions. Her second presentation outlined the types of peer review, the contents of a peer review report by an MDPI reviewer, and the responsibilities of an MDPI reviewer.

MDPI Romania also hosted an author training session at the Iasi University of Life Sciences on 29 May 2024. JRSs Laurentiu Preda and Cosmin Artan gave four presentations: Efficient Writing of an ISI-Indexed Scientific Article, Benefits of Publishing in the Open Access Model, Various Methods of Open Access Publishing, and MDPI Guide for the Article Review Process. The first three presentations offered guidance on how to improve academic writing, the fourth focused on how to write peer review reports. A highly interactive discussion followed the presentations, during which the JRSs provided extensive answers to attendees’ questions.

MDPI is grateful for all the attendees, speakers, and organizers involved in these events. Through their enthusiasm and dedication, these events were great successes.
1 August 2024
Meet Us at the 2024 CAMO Annual Scientific Meeting, 24–26 October 2024, Ottawa, ON, Canada
Conference: 2024 CAMO Annual Scientific Meeting
Date: 24–26 October 2024
Location: Ottawa, ON, Canada
The Canadian Association of Medical Oncologists (CAMO) is a national specialty society of the Royal College of Physicians and Surgeons of Canada. Their mission is to contribute to cancer control, through research, education, and clinical practice in prevention, screening, diagnosis, treatment, supportive care, palliative care, and rehabilitation. The Association is committed to achieving and maintaining, among its members, excellence in clinical and scholarly activity, within a culture of compassion and respect for human dignity. CAMO Annual Scientific Meetings have been held since 2014.
The following MDPI journals will be represented at the 2024 CAMO Annual Scientific Meeting:
- Current Oncology;
- Cancers;
- Life;
- Onco;
- Women;
- Journal of Personalized Medicine;
- Journal of Molecular Pathology.
Our delegates look forward to meeting you in person at the booth at the conference and answering any questions you may have. For more information regarding the conference, please visit the following link: https://camo-acom.ca/page-1549450.
1 August 2024
Current Oncology | World Lung Cancer Day
World Lung Cancer Day is marked on 1st August every year with the aim of raising awareness about lung cancer and promoting prevention, screening, and treatment. This global event seeks to increase public understanding of the risk factors associated with lung cancer and drive governments, organizations, and individuals to take action in order to reduce the incidence and mortality rates of lung cancer. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and a high-quality Special Issue in the related fields published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.
“Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology”
by Hamid Mithoowani and Michela Febbraro
Curr. Oncol. 2022, 29(3), 1828–1839; https://doi.org/10.3390/curroncol29030150
Available online: https://www.mdpi.com/1718-7729/29/3/150
“ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date”
by Sébastien Gendarme, Olivier Bylicki, Christos Chouaid and Florian Guisier
Curr. Oncol. 2022, 29(2), 641–658; https://doi.org/10.3390/curroncol29020057
Available online: https://www.mdpi.com/1718-7729/29/2/57
“Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence”
by Ilaria Attili, Antonio Passaro, Pasquale Pisapia, Umberto Malapelle and Filippo de Marinis
Curr. Oncol. 2022, 29(1), 255–266; https://doi.org/10.3390/curroncol29010024
Available online: https://www.mdpi.com/1718-7729/29/1/24
“Novel Harmonization Method for Multi-Centric Radiomic Studies in Non-Small Cell Lung Cancer”
by Marco Bertolini, Valeria Trojani, Andrea Botti, Noemi Cucurachi, Marco Galaverni, Salvatore Cozzi, Paolo Borghetti, Salvatore La Mattina, Edoardo Pastorello, Michele Avanzo et al.
Curr. Oncol. 2022, 29(8), 5179–5194; https://doi.org/10.3390/curroncol29080410
Available online: https://www.mdpi.com/1718-7729/29/8/410
“Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer”
by Steven Olsen, Jiemin Liao and Hidetoshi Hayashi
Curr. Oncol. 2022, 29(7), 4811–4826; https://doi.org/10.3390/curroncol29070382
Available online: https://www.mdpi.com/1718-7729/29/7/382
“Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options”
by Francesco Petrella, Stefania Rizzo, Ilaria Attili, Antonio Passaro, Thomas Zilli, Francesco Martucci, Luca Bonomo, Filippo Del Grande, Monica Casiraghi, Filippo De Marinis et al.
Curr. Oncol. 2023, 30(3), 3160–3175; https://doi.org/10.3390/curroncol30030239
Available online: https://www.mdpi.com/1718-7729/30/3/239
“Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices”
by Brandon S. Sheffield, Kiefer Eaton, Bruno Emond, Marie-Hélène Lafeuille, Annalise Hilts, Patrick Lefebvre, Laura Morrison, Andrea L. Stevens, Emmanuel M. Ewara and Parneet Cheema
Curr. Oncol. 2023, 30(2), 2348–2365; https://doi.org/10.3390/curroncol30020180
Available online: https://www.mdpi.com/1718-7729/30/2/180
“Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives”
by Chiara Lazzari, Calogera Claudia Spagnolo, Giuliana Ciappina, Martina Di Pietro, Andrea Squeri, Maria Ilenia Passalacqua, Silvia Marchesi, Vanesa Gregorc and Mariacarmela Santarpia
Curr. Oncol. 2023, 30(4), 3684–3696; https://doi.org/10.3390/curroncol30040280
Available online: https://www.mdpi.com/1718-7729/30/4/280
Relevant Special issue:
“Current State of Immunotherapy for Lung Cancer”
Guest Editor: Prof. Dr. Barbara Melosky
You are welcome to submit relevant papers to the journal Current Oncology. For any questions, feel free to contact us.
Current Oncology Editorial Office
11 July 2024
Current Oncology | 30th Anniversary
This year marks the 30th anniversary of Current Oncology (ISSN: 1718-7729), a peer-reviewed open access journal on clinical oncology. With an Impact Factor of 2.8 and a CiteScore of 3.3, the journal is covered in Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases. The journal has published more than 4,100 papers from more than 17,200 authors, who are from 101 countries. This breakthrough could not have been achieved without our readers, authors, peer reviewers, editors, and all the people working for the journal who have combined their tremendous efforts over the years.
We invite you to explore our dedicated webpage, where you will find special content commemorating this milestone: https://www.mdpi.com/journal/curroncol/anniversary.
We have prepared a video showcasing the evolution of Current Oncology and featuring warm congratulations from our Editor-in-Chief, Prof. Dr. Shahid Ahmed.
30th Anniversary Special Issue:
“The 30th Anniversary of Current Oncology: Perspectives in Clinical Oncology Practice”

If you have any questions, suggestions, or recommendations, please do not hesitate to contact us at currentoncology@mdpi.com.
Current Oncology Editorial Office
10 July 2024
MDPI's Newly Launched Journals in June 2024
Five new journals covering multiple subjects have launched their inaugural issue in June 2024. We are excited to be able to share with you the newest research rooted in the value of open access.
We would like to express our deepest appreciation to all the Editorial Board Members and each journal will ensure its high-quality output using excellent editorial and rigorous peer review processes, to ensure that the articles achieve high impact and visibility.
Please feel free to browse and discover more about the new journals below.
|
Journal |
Founding Editor-in-Chief |
Journal Topics (Selected) |
![]() |
Prof. Dr. Marco Ranucci, IRCCS Policlinico San Donato, Italy |
anaesthetic medications; blood and fluid management; pain management; critical care; critical illness | view journal scope | submit an article |
![]() |
Dr. Giovanni E. Cacciamani, University of Southern California, USA |
surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article |
![]() |
Prof. Dr. Gassan Hodaifa, Universidad Pablo de Olavide, Spain |
laboratory management; laboratory safety; protective equipment; laboratory problems and challenges; laboratory Innovation | view journal scope | submit an article |
![]() |
Prof. Dr. Jan S. Suchodolski, Texas A&M University, USA |
companion animals health and disease; veterinary care and nutrition; genetics and genomics; behavior and welfare; human-animal relations | view journal scope | submit an article |
![]() |
Prof. Dr. Pierfrancesco De Paola, University of Naples Federico II, Italy |
real estate appraisal; economic and financial valuation of real estate projects; sustainable real estate; housing and urban economics | view journal scope | submit an article |
We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com) if you would like to create more new journals.
5 July 2024
Current Oncology | Sarcoma and Bone Cancer Awareness Month
July is Sarcoma and Bone Cancer Awareness Month, which is an important campaign dedicated to increasing the awareness and understanding of these unique and challenging diseases. Sarcomas are a rare group of cancers that originate in the bones or soft tissues of the body. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings and high-quality Special Issues in the related fields, published in Current Oncology (ISSN: 1718-7729). We hope this announcement will provide useful information for this field.
“Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment”
by Matthew Ho, Alexander Xiao, Dongni Yi, Saurabh Zanwar and Giada Bianchi
Curr. Oncol. 2022, 29(11), 8975-9005; https://doi.org/10.3390/curroncol29110705
Available online: https://www.mdpi.com/1718-7729/29/11/705
“Minimally Invasive Interventional Procedures for Metastatic Bone Disease: A Comprehensive Review”
by Nicolas Papalexis, Anna Parmeggiani, Giuliano Peta, Paolo Spinnato, Marco Miceli and Giancarlo Facchini
Curr. Oncol. 2022, 29(6), 4155-4177; https://doi.org/10.3390/curroncol29060332
Available online: https://www.mdpi.com/1718-7729/29/6/332
“Safety and Feasibility of Steerable Radiofrequency Ablation in Combination with Cementoplasty for the Treatment of Large Extraspinal Bone Metastases”
by Claudio Pusceddu, Davide De Francesco, Nicola Ballicu, Domiziana Santucci, Salvatore Marsico, Massimo Venturini, Davide Fior, Lorenzo Paolo Moramarco and Eliodoro Faiella
Curr. Oncol. 2022, 29(8), 5891-5900; https://doi.org/10.3390/curroncol29080465
Available online: https://www.mdpi.com/1718-7729/29/8/465
“Updates in Pathology for Retroperitoneal Soft Tissue Sarcoma”
by Tanner Mack and Bibianna Purgina
Curr. Oncol. 2022, 29(9), 6400-6418; https://doi.org/10.3390/curroncol29090504
Available online: https://www.mdpi.com/1718-7729/29/9/504
“Staging Systems and Nomograms for Soft Tissue Sarcoma”
by Maria Danieli and Alessandro Gronchi
Curr. Oncol. 2023, 30(4), 3648-3671; https://doi.org/10.3390/curroncol30040278
Available online: https://www.mdpi.com/1718-7729/30/4/278
“Surgical Management of Retroperitoneal Sarcoma”
by Dana A. Dominguez, Sagus Sampath, Mark Agulnik, Yu Liang, Bao Nguyen, Vijay Trisal, Laleh G. Melstrom, Aaron G. Lewis, Isaac Benjamin Paz, Randall F. Roberts et al.
Curr. Oncol. 2023, 30(5), 4618-4631; https://doi.org/10.3390/curroncol30050349
Available online: https://www.mdpi.com/1718-7729/30/5/349
The list of relevant Special Issues is as follows:
“Treatment of Bone Metastasis”
Guest Editor: Dr. Costantino Errani
Available online: https://www.mdpi.com/journal/curroncol/special_issues/Treatment_Bone_Metastasis
“Bone and Soft Tissue Tumors: Clinical Features, Imaging and Treatment”
Guest Editors: Dr. Andrea Sambri, Dr. Michele Fiore and Dr. Massimiliano De Paolis
Available online: https://www.mdpi.com/journal/curroncol/special_issues/COMBGQV12M
“What’s New in Musculoskeletal Oncology?”
Guest Editors: Dr. Andreas F. Mavrogenis, Dr. Costantino Errani and Dr. Shinji Tsukamoto
Available online: https://www.mdpi.com/journal/curroncol/special_issues/J418745AG0
You are welcome to submit relevant papers to the Current Oncology journal. For any questions, please feel free to contact us.
Current Oncology Editorial Office
26 June 2024
Current Oncology Receives an Updated Impact Factor of 2.8 and CiteScore of 3.3
We are pleased to share that the Current Oncology (ISSN: 1718-7729) was awarded an increased Impact Factor of 2.8 in the 2023 Journal Citation Reports™ released by Clarivate in June 2024. The Current Oncology ranks upgraded from Q3 to Q2 (157 among 322 titles) in the “Oncology” category.
Additionally, according to data released by Scopus (Elsevier), the Current Oncology received an updated CiteScore™ of 3.3, an increase of 27% compared with the 2022 metric. Current Oncology’s CiteScore ranks Q3 (238 among 404 titles) in the “Oncology” category.
|
2.82023 Impact Factor |
157/322 (Q2)Oncology |
6,836Citations in 2023 |
|
3.32023 CiteScore |
238/404 (Q3)Oncology |
0.792SNIP |
For further statistics, please visit https://www.mdpi.com/journal/curroncol/stats. For more information about MDPI flagship journals' citation metrics, please see here.
At MDPI, our mission is simple yet powerful, and we strive every day to make scientific research freely accessible to everyone, everywhere. With over 3.5 million authors choosing MDPI, we have established ourselves as a key player driving the open access initiative.
Our journals have received over 13 million citations in the Web of Science, making us the most cited open access publisher. With over 800 institutional partners, MDPI continues to demonstrate its dedication to providing reliable and collaborative publishing services.
Current Oncology Editorial Office










